

The Role of International Organizations in Expanding Access to Antiretroviral Therapy (ART) in East Africa

Nyambura Achieng M.

School of Natural and Applied Sciences Kampala International University Uganda

ABSTRACT

HIV/AIDS continues to be a significant public health challenge in East Africa, despite substantial progress over the past two decades. A critical driver of success in expanding access to antiretroviral therapy (ART) across countries such as Kenya, Uganda, and Tanzania have been the involvement of international organizations. This review explores the multifaceted role of global actors—including the World Health Organization (WHO), Joint United Nations Programme on HIV/AIDS (UNAIDS), the Global Fund, the U.S. President's Emergency Plan for AIDS Relief (PEPFAR), and Médecins Sans Frontières (MSF)—in scaling up ART delivery in the region. It examines how these organizations have contributed through financial investment, drug procurement, policy advocacy, technical support, and capacity building. The review highlights the remarkable achievements enabled by international partnerships, such as improved ART coverage, reduced HIV-related mortality, decentralized treatment access, and prevention of mother-to-child transmission. However, it also identifies persistent challenges, including overreliance on external funding, supply chain disruptions, workforce shortages, stigma, and coordination inefficiencies. By analyzing both the successes and limitations of international interventions, this review offers evidence-based insights and policy recommendations aimed at enhancing the sustainability and effectiveness of ART programs. It underscores the importance of aligning global support with national priorities and fostering resilient health systems capable of addressing current needs and future public health threats.

Keywords: Antiretroviral Therapy (ART), HIV/AIDS, East Africa, International Organizations the Global Fund.

INTRODUCTION

HIV/AIDS remains a pressing public health crisis in East Africa, with countries such as Kenya, Uganda, and Tanzania experiencing some of the highest HIV prevalence rates in the world [1]. The epidemic has had far-reaching health, economic, and social consequences, weakening healthcare systems, reducing labor productivity, and increasing the burden on families and communities [2]. Since its emergence in the 1980s, the HIV/AIDS epidemic has evolved from a fatal diagnosis to a manageable chronic illness, largely due to the development and widespread use of antiretroviral therapy (ART) [3].

Antiretroviral therapy is a life-saving intervention that suppresses the replication of the human immunodeficiency virus (HIV) within the body, thereby improving the health and life expectancy of individuals living with the virus [4]. In addition to its therapeutic benefits, ART significantly reduces the risk of HIV transmission, making it a key strategy in achieving the ambitious goal of ending AIDS as a public health threat by 2030, as outlined in the United Nations Sustainable Development Goals (SDGs) [5].

Despite the transformative potential of ART, access to these medications remains uneven, particularly in low- and middle-income countries, including those in East Africa [6]. Structural challenges such as limited healthcare infrastructure, shortages of skilled personnel, poverty, and stigma continue to hinder effective ART delivery. Moreover, the high cost of ART and the need for long-term adherence have posed additional barriers to treatment access and retention in care.

In this context, international organizations have played an indispensable role in the expansion and sustainability of ART programs in East Africa [7]. Organizations such as the World Health Organization (WHO), the Joint United Nations Programme on HIV/AIDS (UNAIDS), the Global Fund to Fight AIDS, Tuberculosis and Malaria, the U.S.

President's Emergency Plan for AIDS Relief (PEPFAR), and Médecins Sans Frontières (MSF) have been instrumental in mobilizing resources, providing technical assistance, strengthening health systems, and promoting evidence-based interventions [8].

Through financial support, drug procurement, health workforce training, and advocacy, these organizations have helped East African countries significantly expand access to ART. Their involvement has not only saved millions of lives but also contributed to the normalization of HIV testing and treatment, integration of services into primary healthcare, and a reduction in new infections [9].

Although substantial progress has been made in expanding ART access in East Africa, many challenges persist. Despite the support from international organizations, there are still disparities in ART coverage, especially among rural populations, adolescents, and key affected populations such as sex workers, men who have sex with men, and people who inject drugs [10]. In some areas, stockouts of antiretroviral drugs, weak health information systems, and poor retention in care continue to undermine the effectiveness of ART programs.

Furthermore, the sustainability of ART programs remains a critical concern, particularly in the face of fluctuating donor priorities and funding reductions. Over-reliance on external aid poses a risk to long-term treatment continuity. National governments often face difficulties in scaling up domestic financing to fill potential funding gaps, raising questions about the resilience and self-sufficiency of national ART programs [11].

There is also a need for a comprehensive understanding of the specific contributions of different international organizations, how their approaches complement or overlap, and what lessons can be learned to inform future interventions. While many evaluations have focused on clinical outcomes, fewer studies have examined the structural and institutional roles of international organizations in expanding ART access. This gap limits the ability of policymakers and stakeholders to replicate successful strategies and adapt interventions to changing contexts [12]. This study is designed with specific objectives that collectively aim to enhance understanding of the pivotal role international organizations play in the expansion and sustainability of antiretroviral therapy (ART) programs in East Africa. It seeks to analyze the contributions of major international actors such as the World Health Organization (WHO), UNAIDS, PEPFAR, and the Global Fund, particularly in scaling up ART availability and improving service quality. The study further investigates the strategies and operational mechanisms employed by these bodies—ranging from funding and technical assistance to policy advocacy and capacity building—that have facilitated ART access across the region. Additionally, the research delves into the challenges and limitations faced by these organizations, including funding constraints, logistical barriers, political dynamics, and coordination issues with local health systems. A key focus is placed on assessing the impact of international interventions on national ART coverage, program sustainability, and broader health system strengthening. The study aims to offer evidence-based recommendations to improve the coordination, efficiency, and long-term viability of international support in the region. To guide the research, core questions address the roles and strategies of international organizations, the challenges they face, the impact of their interventions, and potential strategies for enhancing collaboration and outcomes. The significance of this study lies in its ability to provide critical insights into how international partnerships can be harnessed to address public health challenges in low-resource settings. It contributes to policymaking by helping governments and donors better understand what works, where improvements are needed, and how international support can align with national priorities. Moreover, the study enriches scholarly discourse on global health governance by examining the interface between international aid and domestic health systems. In an era marked by emerging global health threats and shifting donor priorities, lessons from East Africa's ART experience can inform the development of resilient, adaptable, and equitable healthcare systems worldwide.

Overview of HIV/AIDS and ART in East Africa

East Africa has experienced significant progress in the fight against HIV/AIDS over the past twenty years, marking a remarkable public health achievement despite ongoing resource constraints [13]. The widespread introduction and scaling up of antiretroviral therapy (ART) across the region have been central to this progress. ART availability has expanded dramatically, resulting in substantial reductions in HIV-related mortality rates and a marked decrease in mother-to-child transmission of the virus [14]. Data from UNAIDS indicate that ART coverage in East African countries was less than 10% in 2003 but increased to over 80% in some nations by 2023, highlighting the success of national HIV programs and regional efforts. This positive trend reflects not only improvements in healthcare infrastructure but also the critical role of international partnerships and funding from global health initiatives such as the Global Fund, PEPFAR, and UNAIDS. These programs have supported testing, treatment, and community awareness campaigns, improving early diagnosis and adherence to ART. Despite this progress, challenges remain, including ensuring consistent drug supply, addressing stigma, and reaching marginalized populations. Nonetheless, East Africa's strides in expanding ART access demonstrate the potential for continued advances in controlling the HIV/AIDS epidemic through coordinated efforts, sustained investment, and integration of HIV services into broader healthcare systems [15].

Key International Organizations and Their Contributions

International organizations have played a pivotal role in advancing HIV/AIDS treatment and care in East Africa, significantly contributing to the expansion and improvement of antiretroviral therapy (ART) programs [16]. The World Health Organization (WHO) has provided essential technical guidance by setting global ART treatment standards and helping national health ministries implement evidence-based protocols. WHO's key contributions in the region include offering normative guidance on ART initiation and monitoring, supporting the adoption of the "Treat All" policy, and facilitating pharmacovigilance and drug resistance surveillance to ensure treatment efficacy [17]. UNAIDS has been instrumental in coordinating global efforts to end AIDS, promoting universal access to ART through ambitious initiatives such as the 90-90-90 and 95-95-95 targets. It also mobilizes political will, tracks progress, and strengthens strategic information systems to monitor HIV services effectively. The Global Fund to Fight AIDS, Tuberculosis and Malaria acts as a major financier, supporting ART procurement, health system strengthening, including training and laboratory capacity, and community-based HIV testing and linkage to care programs. The President's Emergency Plan for AIDS Relief (PEPFAR), as one of the largest funders, has contributed billions towards ART access, laboratory infrastructure, workforce development, and targeted prevention programs for key populations. Complementing these multilateral efforts, Non-Governmental Organizations (NGOs) and Faith-Based Organizations (FBOs) deliver ART at the community level, provide patient education and adherence support, and work to overcome stigma and cultural barriers that hinder ART uptake. Together, these organizations form a comprehensive network that drives the ongoing fight against HIV/AIDS in East Africa [18].

Achievements and Impact

International support has played a pivotal role in transforming the landscape of HIV/AIDS treatment and care across East Africa, yielding significant achievements and widespread impact. One of the most notable outcomes has been the dramatic improvement in antiretroviral therapy (ART) coverage [19]. Thanks to sustained funding, technical assistance, and collaborative initiatives from international organizations, the enrollment of people living with HIV into ART programs has surged across multiple countries in the region. This expanded access to treatment has directly contributed to substantial reductions in both mortality and morbidity associated with HIV/AIDS. Earlier initiation of ART, facilitated by improved testing and linkage to care, has been critical in decreasing the number of HIV-related deaths and enhancing the quality of life for those affected.

In addition to treatment advancements, international support has been instrumental in preventing mother-to-child transmission (PMTCT) of HIV. Comprehensive ART programs targeting pregnant women have dramatically lowered vertical transmission rates, safeguarding new generations from the virus and marking a major public health success. Beyond these clinical outcomes, the decentralization of ART delivery has been a transformative development. Treatment services, once confined to specialized hospitals, have now expanded into primary healthcare facilities and community-based settings. This decentralization has increased accessibility, reduced travel burdens for patients, and improved retention in care, particularly in rural and underserved areas. Collectively, these achievements highlight how international collaboration has not only strengthened health systems but also fostered more equitable and sustainable HIV care in East Africa, ultimately moving the region closer to controlling the epidemic [20].

Challenges and Gaps

Despite notable successes in expanding antiretroviral therapy (ART) programs, several persistent challenges and gaps continue to hinder optimal HIV/AIDS management. A primary concern is the heavy reliance of many national programs on international funding sources [21]. This dependency poses significant risks to the long-term sustainability of HIV interventions, especially as global priorities and donor interests shift. Furthermore, frequent disruptions in the supply chain lead to drug stockouts, which directly impact the consistent availability of ART medications. Such interruptions not only compromise treatment effectiveness but also contribute to drug resistance and patient attrition. Compounding these issues is the critical shortage of trained healthcare personnel, particularly in rural and underserved areas. The scarcity of skilled workers limits the quality and reach of HIV services, reducing the capacity to provide comprehensive care and follow-up. Additionally, stigma and discrimination remain formidable barriers to effective ART adherence. Deeply rooted cultural beliefs and societal attitudes often discourage individuals from seeking testing, treatment, or continuing their therapy, exacerbating the risk of poor health outcomes. Lastly, the complexity of coordination among the numerous stakeholders involved in HIV/AIDS care—ranging from government agencies and international organizations to local NGOs—can result in fragmentation and duplication of efforts. This lack of streamlined collaboration undermines efficiency and sometimes causes confusion among beneficiaries. Addressing these challenges requires integrated, sustainable approaches that strengthen health

systems, improve supply chains, enhance workforce capacity, combat stigma, and foster better coordination among all actors involved in HIV care [22].

Future Directions and Recommendations

To sustain and build on the progress made in HIV treatment and care, international organizations and partners must adopt a multi-faceted approach focused on strengthening health systems, increasing domestic financing, fostering community involvement, supporting innovation, and improving coordination. Firstly, promoting domestic resource mobilization is critical; governments should be encouraged to allocate increased budgets toward health financing, particularly for antiretroviral therapy (ART), to reduce dependence on external funding and ensure long-term sustainability [23]. Secondly, health systems require significant strengthening through investments in workforce training, robust data management systems, and efficient logistics to guarantee consistent ART availability and quality care. Thirdly, community engagement should be scaled up by empowering community-led monitoring and service delivery models, which have proven effective in improving adherence and outreach. Fourthly, innovation must be supported by expanding differentiated service delivery models that tailor care to individual needs, as well as adopting long-acting ART formulations that reduce treatment burden and improve patient outcomes. Finally, enhanced coordination between donors, government agencies, and civil society organizations is essential to streamline efforts, minimize duplication, and optimize resource use. Together, these strategies will reinforce the foundations of HIV care programs, driving progress toward epidemic control and ensuring equitable access to lifesaving treatment for all affected populations.

CONCLUSION

In conclusion, international organizations have been indispensable in expanding access to antiretroviral therapy (ART) across East Africa, significantly transforming HIV/AIDS treatment and improving health outcomes. Their contributions ranging from funding and technical support to advocacy and capacity building have enabled substantial increases in ART coverage, reduced mortality, and curbed mother-to-child transmission. These efforts have helped integrate HIV services into primary healthcare, enhancing accessibility and retention in care, especially in underserved communities. However, challenges such as reliance on external funding, supply chain disruptions, workforce shortages, stigma, and coordination complexities persist, threatening the sustainability and effectiveness of ART programs. Moving forward, a strategic emphasis on promoting domestic resource mobilization, strengthening health systems, fostering community engagement, supporting innovative service delivery models, and enhancing coordination among all stakeholders is essential. Such multi-dimensional approaches will help ensure that gains are sustained and that ART programs become more resilient, equitable, and responsive to evolving needs. Ultimately, continued collaboration between international partners and national governments will be critical to achieving long-term control of the HIV epidemic in East Africa and fulfilling global commitments to end AIDS as a public health threat by 2030.

REFERENCES

1. Parker, E., Judge, M.A., Macete, E., Nhampossa, T., Dorward, J., Langa, D.C., et al: HIV infection in Eastern and Southern Africa: Highest burden, largest challenges, greatest potential. *South Afr J HIV Med.* 22, 1237 (2021). <https://doi.org/10.4102/sajhivmed.v22i1.1237>
2. Obeagu, E.I., Alum, E.U. and Obeagu, G.U. Factors Associated with Prevalence of HIV Among Youths: A Review of Africa Perspective. *Madonna University Journal of Medicine and Health Sciences*, 2023; 3(1): 13-18. <https://madonnauniversity.edu.ng/journals/index.php/medicine>
3. Swinkels, H.M., Nguyen, A.D., Gulick, P.G.: HIV and AIDS. In: *StatPearls*. StatPearls Publishing, Treasure Island (FL) (2025)
4. HIV/AIDS | WHO | Regional Office for Africa, <https://www.afro.who.int/health-topics/hivaids>
5. Aja, P. M., Okon, M. B., Uti, D. E., Ugwu, O. P. C., Obeagu, E. I. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research.* 2023; 11(10):01-06. DOI: 10.58538/IJAR/2048. <http://dx.doi.org/10.58538/IJAR/2048>
6. Abah, V.O.: Poor Health Care Access in Nigeria: A Function of Fundamental Misconceptions and Misconstruction of the Health System. Presented at the November 7 (2022)
7. Madu, C.V., Alum, E.U., Aloh, H.E., Ugwu, O.P.C., Obeagu, E.I., Uti, D.E., Egba, S.I., et al. The price of progress: Assessing the financial costs of HIV/AIDS management in East Africa. *Medicine (Baltimore)*. 2025 May 2;104(18):e42300. doi: 10.1097/MD.00000000000042300. PMID: 40324279; PMCID: PMC12055164.

8. Ogieuhi, I.J., Ajekiigbe, V.O., Aremu, S.O., Okpujie, V., Bassey, P.U., Babalola, A.E., Gbolagade-Jonathan, P., Anthony, C.S., Bakare, I.S.: Global partnerships in combating tropical diseases: assessing the impact of a U.S. withdrawal from the WHO. *Trop Med Health*. 53, 36 (2025). <https://doi.org/10.1186/s41182-025-00722-8>
9. Alum, E. U., Obeagu, E. I., Ugwu, O. P. C., Samson, A. O., Adepoju, A. O., Amusa, M. O. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41):e35673. <http://dx.doi.org/10.1097/MD.00000000000035673>. PMID: 37832059; PMCID: PMC10578718.
10. Atuhaire, L., Shumba, C.S., Mapahla, L., Nyasulu, P.S.: A retrospective cross sectional study assessing factors associated with retention and non-viral suppression among HIV positive FSWs receiving antiretroviral therapy from primary health care facilities in Kampala, Uganda. *BMC Infect Dis*. 22, 642 (2022). <https://doi.org/10.1186/s12879-022-07614-w>
11. Uti, D.E., Echegu, D.A., Egba, S.I., Ukaidi, C.U.A. Confronting Dual Challenges: Substance Abuse and HIV/AIDS. *Elite Journal of HIV*, 2024; 2(5): 1-8. <https://epjournals.com/journals/EJHIV>
12. Skivington, K., Matthews, L., Simpson, S.A., Craig, P., Baird, J., Blazeby, J.M., et al.: Framework for the development and evaluation of complex interventions: gap analysis, workshop and consultation-informed update. *Health Technol Assess*. 25, 1–132 (2021). <https://doi.org/10.3310/hta25570>
13. Alum, E. U., Ugwu, O. P.C., Obeagu, E. I., Okon, M. B. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*, 2023; 3(2): 28-31. <https://nijournals.org/wp-content/uploads/2023/06/NIJRMS-32-28-31-2023-rm.pdf>
14. Ezeonwumelu J O C, Ntale M, Kasozi K I, Byarugaba F (2017). In vitro Antibacterial Efficacy of *Bidenspilosa*, *Ageratum conyzoides* and *Ocimum suave* extracts against HIV/AIDS patients' oral bacteria in south-western Uganda. *Pharmacology & Pharmacy*.
15. Mugisha S, Agwu E (2015). Cross-border movement of people and its effect on the Spread of HIV/AIDS in Kisoro district south western Uganda. *Special viral Pathogens Journal*, 1, (1), 0026-0037.
16. El-Sadr, W.M., Holmes, C.B., Mugenyi, P., Thirumurthy, H., Ellerbrock, T., Ferris, R., et al.: Scale-up of HIV Treatment Through PEPFAR: A Historic Public Health Achievement. *J Acquir Immune Defic Syndr*. 60, S96-104 (2012). <https://doi.org/10.1097/QAI.0b013e31825eb27b>
17. CLINICAL GUIDELINES: ANTIRETROVIRAL THERAPY. Presented at the (2016)
18. Agwu E, Ihongbe J. C, Ezeonwumelu J. O, Moazzam M, Lodhi M. M (2015). Baseline burden and antimicrobial susceptibility of pathogenic bacteria recovered from oral lesions of patients with HIV/AIDS in South-Western Uganda. *Oral Science International*, 12, (2), 59-66. [https://doi.org/10.1016/S1348-8643\(15\)00018-X](https://doi.org/10.1016/S1348-8643(15)00018-X).
19. Angbalaga A, Ani C C, Atsukwei D, Eze E D, Afodun A M, Igoh E O, et al (2018). Correlation of hepatobiliary ultrasonographic findings with cd4cell count and liver enzymes in adult hiv/aids patients in Jos. *Journal of AIDS and HIV Research*, 10, (6), 83-95.
20. Ezeonwumelu C J O, Muhammad N, Okwudili O. S, Agwu E, Kihdze T. J, Adebowale A A., et al. Analgesic Appraisal of *Bidens pilosa* (Asteraceae) Leaf Extracts Used in Management of Oral Lesion Pain in HIV/AIDS Patients in Rodents.
21. Bouabida, K., Chaves, B.G., Anane, E.: Challenges and barriers to HIV care engagement and care cascade: viewpoint. *Front Reprod Health*. 5, 1201087 (2023). <https://doi.org/10.3389/frph.2023.1201087>
22. Ihongbe J C, Moazzam M I, Pazos V, Agwu E (2015). Non-target oral bacterial resistance to Cotrimoxazole in HIV/AIDS patients living in South Western Uganda. *Spec. Bact. Pathog. J*, 1, (1), 01-08.
23. Ugwu, O.P.C., Alum, E.U., Uti, D.E., Alum, B.N. Toward a cure - Advancing HIV/AIDS treatment modalities beyond antiretroviral therapy: A Review. *Medicine (Baltimore)*. 2024 Jul 5;103(27):e38768. doi: 10.1097/MD.00000000000038768. PMID: 38968496.

CITE AS: Nyambura Achieng M. (2025). The Role of International Organizations in Expanding Access to Antiretroviral Therapy (ART) in East Africa. EURASIAN EXPERIMENT JOURNAL OF MEDICINE AND MEDICAL SCIENCES, 6(3):105-109